Penfluridol is an antipsychotic medication for schizophrenia that offers long-acting effects. Penfluridol’s action reduces dosing frequency, improves adherence, and is cost-effective in resource-limited healthcare settings.

Product successfully added to Quote Basket!
View Quote Basket

Long-lasting effects according to clinical trials

Low cost compared to other antipsychotics

Demonstrated efficacy in managing symptoms

Penfluridol’s extended therapeutic duration leads to reduced dosing frequency, fostering patient adherence to schizophrenia treatment. Its cost-effectiveness compared to newer antipsychotics widens access to psychiatric care, especially in resource-constrained healthcare environments. 

About MedicaPahrma

MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.

What is Penfluridol

Penfluridol is an antipsychotic medication prescribed to patients diagnosed with schizophrenia.

Why Choose MedicaPharma

We are committed to supplying high-quality GMP products with logistics according to GDP regulations.

Table of Contents

Penfluridol is a potent antipsychotic pharmaceutical with long-lasting effects used primarily in the treatment of schizophrenia.

Mechanism of Action

Penfluridol works primarily through antagonism of dopamine D2 receptors in the central nervous system. By blocking these receptors, penfluridol inhibits dopamine neurotransmission, leading to a reduction in dopaminergic activity. This action helps alleviate the positive symptoms of schizophrenia, such as hallucinations and delusions, which are believed to be associated with excessive dopamine signaling in certain brain regions. Furthermore, penfluridol’s long-acting nature contributes to sustained dopamine receptor blockade, prolonging its therapeutic effects and allowing for less frequent dosing.

Benefits and Advantages

Penfluridol offers the advantage of prolonged therapeutic effects due to its long-acting nature, reducing the frequency of dosing and enhancing patient adherence in the treatment of schizophrenia. Its affordability relative to newer antipsychotics makes it a cost-effective option, particularly in healthcare settings with limited resources, ensuring broader access to effective psychiatric care. Additionally, penfluridol’s mechanism of action, primarily through dopamine D2 receptor antagonism, provides robust efficacy in alleviating the positive symptoms of schizophrenia, contributing to improved patient outcomes and long-term stability.

Side Effects and Risks

  • Movement disorders such as dystonia, parkinsonism, and tardive dyskinesia due to its dopamine receptor antagonism, particularly with long-term use or high doses.
  • Neuroleptic malignant syndrome (NMS): Although rare, penfluridol, like other antipsychotic medications, carries a risk of causing NMS, a potentially life-threatening condition characterized by hyperthermia, altered mental status, autonomic dysfunction, and muscle rigidity.
  • Cardiac effects: Penfluridol may increase the risk of arrhythmias, including torsades de pointes, especially in individuals with preexisting cardiac conditions or those taking other medications that also prolong the QT interval.
  • Sedation and cognitive impairment: Penfluridol can cause sedation and cognitive impairment, affecting concentration, memory, and overall cognitive function, which may impact daily activities and quality of life.
  • Metabolic effects: Penfluridol use has been associated with metabolic side effects such as weight gain, dyslipidemia, and hyperglycemia, increasing the risk of cardiovascular disease and diabetes mellitus, particularly in susceptible individuals.

Penfluridol FAQ

Penfluridol, an antipsychotic medication, distinguishes itself through potent and prolonged dopamine D2 receptor antagonism, making it effective in treating schizophrenia. Its extended half-life allows for less frequent dosing, improving patient compliance, while its affordability renders it a practical choice, especially in resource-constrained healthcare settings.

MedicaPharma, a supplier based in the European Union, offers GMP products with GDP-compliant logistics to hospitals, pharmacies, commercial (compounding) pharmacies, research institutes, and universities. For inquiries or to request a quote, please click here.

When choosing a pharmaceutical supplier, it’s vital to prioritize reliability, ensuring consistent and timely delivery of high-quality products. Additionally, expertise and compliance with regulatory standards are essential to guarantee the safety and efficacy of pharmaceutical supplies.

EU-based supplier MedicaPharma provides high-quality GMP products with logistics according to GDP regulations to leading sales, research, and education institutions. Click here to request a quote.